December 2011

Costly protease inhibitors work well in many patients, but call for careful monitoring

Thomas Reinke

UnitedHealthcare’s VP for oncology says it will take time to come to grips with the cost of chemotherapy, but we have to start now

We look at a few programs designed to address adherence-related behavioral problems

Carol Milano

Although three pilot programs came up short, experts say systems like PROMETHEUS could still succeed — if plan medical directors take an active role

Frank Diamond

COVER STORY

Now that we know there is so much unwarranted deviation in care, payers are promoting comparative effectiveness research and other efforts to help providers embrace the evidence

Joseph Burns

EVIDENCE REVIEW

A summary of the ECRI Institute’s Emerging Technology Evidence Report

LEGISLATION & REGULATION

However, they’ll need to prove it. Powerful interest groups say insurers have little experience with these patients and worry that MCOs will shortchange members.

John Carroll

PLAN WATCH

Healthy Blue Living in Michigan lets employers and members reap the benefits of lifestyle improvement

Frank Diamond

TOMORROW’S MEDICINE

Clinicians can consider this radiotherapy a viable treatment option

Thomas Morrow, MD

VIEWPOINT

Weighing the risks and benefits of any treatment to decide whether it is worth pursuing takes a kind of knowledge that most in health care lack

Brent C. James, MD

NEWS & COMMENTARY

NEWS & COMMENTARY

Leave a Comment